AI-powered medical diagnosisprimary
3 projects
Founded their H2020 portfolio on the Symptoma project for rare disease diagnosis, then applied diagnostic AI capabilities across PERSIST and AICCELERATE.
Organization
SYMPTOMA GMBH
Austrian health-tech SME developing AI-powered diagnostic and clinical decision support tools for rare diseases and hospital care pathways.
Technology SMEhealthATSMENo active H2020 projects
H2020 projects
3
As coordinator
1
Total EC funding
€2.8M
Unique partners
33
What they do
Their core work
Symptoma is a Vienna-based health-tech SME that develops AI-powered diagnostic tools, originally focused on helping clinicians identify rare and complex diseases faster. Their core product is an intelligent symptom-to-diagnosis engine that uses artificial intelligence and machine learning. Beyond diagnostics, they have expanded into clinical decision support for cancer survivorship care planning, hospital patient flow optimization, and smart care pathway engines covering surgical and emergency department workflows.
Core expertise
What they specialise in
Rare and complex disease identificationprimary
1 project
The Symptoma project (€1.6M, coordinator role) specifically targeted better diagnosis for patients with rare and complex diseases.
Cancer survivorship and care planningsecondary
1 project
PERSIST project focused on patient-centered survivorship care plans after cancer treatment using big data and AI.
Smart hospital care pathwaysemerging
1 project
AICCELERATE project applies AI to optimize patient flow across surgery, emergency, and discharge processes, including Parkinson's and pediatric care.
Health data interoperability and privacysecondary
2 projects
Both PERSIST and AICCELERATE involve health data integration challenges, with PERSIST explicitly listing interoperability and privacy/security/ethics as core themes.
Evolution & trajectory
How they've shifted over time
Early focus
AI rare disease diagnosis
Recent focus
Clinical AI for hospital workflows
Symptoma began its H2020 journey in 2018 by securing SME Instrument Phase 2 funding to scale its own AI diagnostic product for rare diseases — a classic startup growth move. From 2020 onward, they pivoted from being a product company seeking scale-up funding to becoming a technology partner in larger clinical AI consortia (PERSIST and AICCELERATE), contributing their AI and machine learning capabilities to broader healthcare challenges like cancer survivorship and hospital workflow optimization. This shift from self-funded product development to consortium-embedded AI provider signals growing maturity and market recognition.
Symptoma is moving from a niche diagnostic tool company toward becoming a broader clinical AI platform provider, making them increasingly relevant for any project needing AI-driven patient pathway optimization.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European12 countries collaborated
Symptoma operates as both a project leader and a specialist technology contributor. They coordinated their own flagship project (Symptoma, SME-2) but joined two larger Research and Innovation Action consortia as a participant, suggesting they are comfortable in both roles. With 33 unique partners across 12 countries from just 3 projects, they engage in mid-to-large consortia and bring a specific AI/ML technology contribution rather than broad consulting.
Despite only three projects, Symptoma has built a network of 33 partners across 12 countries, reflecting the large consortium sizes of their RIA and IA projects. Their reach is distinctly pan-European, consistent with health-tech companies integrating clinical data from multiple national health systems.
Why partner with them
What sets them apart
Symptoma brings a production-grade AI diagnostic engine to the table — not a research prototype, but an existing commercial product with real-world deployment experience. This makes them a strong partner for any consortium that needs AI-driven clinical decision support without building from scratch. Their combination of rare disease expertise and broader hospital AI applications is unusual for an SME of their size.
Notable projects
Highlights from their portfolio
- SymptomaTheir flagship project as coordinator with €1.6M in SME Instrument funding, validating their core AI diagnostic product for rare and complex diseases.
- AICCELERATEAmbitious multi-domain hospital AI project spanning surgery, Parkinson's care, and pediatrics — shows Symptoma's expansion beyond diagnostics into full care pathway optimization.
Cross-sector capabilities
Digital health and AI/ML applicationsBig data analytics for clinical decision supportHealth data interoperability and privacy-preserving systemsRobotics-adjacent surgical pathway optimization
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →